Supplementary Materials

The PDF file includes:

  • Fig. S1. Cyclins play a role in CDK4/6i resistance.
  • Fig. S2. Combined CDK4/6i and MDM2i treatment inhibits viability and DNA replication in melanoma cells.
  • Fig. S3. Combined administration of CDK4/6i and MDM2i inhibits proliferation of tumor cells in vivo.
  • Fig. S4. Several protein markers are induced in melanoma PDXs after CDK4/6i and MDM2i treatment.
  • Table S1. Pathway enrichment analysis of genes significantly altered by combined CDK4/6i and MDM2i treatment.
  • Table S2. Antibodies used in this study.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Tumor measurements for experiments shown in Fig. 1A.
  • Data file S2 (Microsoft Excel format). Raw data for the single-nucleotide variation genetic analysis shown in Fig. 1B.
  • Data file S3 (Microsoft Excel format). Raw data for the copy number alteration genetic analysis shown in Fig. 1B.
  • Data file S4 (Microsoft Excel format). Raw data for the RPPA analysis shown in Fig. 1C.
  • Data file S5 (Microsoft Excel format). Tumor measurements for all mouse experiments shown in Fig. 5.
  • Data file S6 (Microsoft Excel format). Mouse weight measurements shown in Fig. 5J.
  • Data file S7 (Microsoft Excel format). Raw data for the analysis of 660 protein biomarkers shown in Fig. 6C.